Advancing the Future of Differentiated Payload & Format Conjugates

Get Ahead of the Next Generation of Conjugates with New Data on Dual-Payload, Pathway-Directed, Degrader & Bispecific Programs from the Teams Taking Them to the Clinic

Novel conjugates have moved from emerging idea to strategic priority. Dual-payload and alternative-mechanism programs are reaching the clinic, the first bispecific ADC has reached the market, and big pharma is backing the space with a wave of deals and acquisitions.

The 6th Novel Conjugates Summit is the only industry-led forum dedicated entirely to novel payloads and targeting formats. There is no traditional ADC content here, just the data, mechanisms and translational lessons from the programs making the most progress.

That shift is changing what discovery teams need from a conference. Classical Topo1 and MMAE payloads face resistance, narrow therapeutic windows and a crowded field, so the questions are now practical: which payload mechanisms justify the added complexity, how to pair payloads and control PK, ratio and tolerability, how to choose between bispecific, biparatopic, peptide and fragment formats, and what preclinical evidence shows a program is ready for IND.

In a room of 80+ discovery, bioconjugation and R&D leaders from big pharma, traditional ADC & novel conjugate biotechs, the focus is depth over volume: science-led sessions, candid discussion of what is working and what is not, and time to connect with everyone attending.

Across a workshop day dedicated to designing novel conjugates with clinical intent, and two single-track conference days which spotlight new data on dual-payload, pathway-directed, degrader and bispecific conjugates, a look at conjugates beyond oncology, and networking built so that no one in the room is out of reach. If your next program depends on what comes after Topo1 and MMAE, this is where your team needs to be in 2027.

  • The summit had good attendance but was not so large as to prevent an opportunity to speak with everyone present. The agenda was also thoughtfully curated, showcasing multiple emerging conjugate formats, discovery methods, and therapeutic approaches that promoted thoughtful discussion.

    Director, Research Innovation & Protein Engineering, Sutro Biopharma, 2026 Attendee

    SutroBiopharma

  • Participating in a small conference where you could get to know many of those working in the same or closely related fields was great. It was also great to see a wide range of conjugate formats discussed.

    Senior Director, Chemistry Engineering & Technical, Prelude Therapeutics, 2024 Attendee 

    Prelude Therapeutics

Explore the 2026 Event Guide

  • 20 Expert Speakers from Big Pharma & Leading Novel Conjugate Biotechs
  • 8+ New Data Presentations on Dual-Payload, Pathway-Directed, Degrader & Bispecific Conjugates
  • Pre-Conference Workshops on Designing Novel Conjugates with Clinical Intent
  • Dedicated Content on Peptides, Oligonucleotides & Conjugates Beyond Oncology
  • Speed Networking, Poster Sessions & Open Q&A Built into the Program

Speakers

Sorry, we couldn't find any posts. Please try a different search.

What To Expect

80+

Discovery, Bioconjugation & R&D Leaders in One Room

3

Days of Science-Led Content & Networking

2

Pre-Conference Workshops

100%

Novel Conjugate Content

Attending Companies Include:

Explore The Agenda - 5th Novel Conjugates Summit
Explore the Agenda

Preview data-led sessions on dual-payload, pathway-directed, degrader and bispecific conjugates, and two pre-conference workshops on rational design and preclinical signposts. Download the event guide for the full agenda and speaker faculty across three days.

Partner With Us - 5th Novel Conjugates Summit
Partner With Us
Meet 80+ discovery, bioconjugation and R&D leaders who are choosing partners for dual-payload, degrader, bispecific and non-antibody programs. Extend your reach beyond the flagship ADC meetings into a room where every attendee is focused on what comes next and inquire to see the partnership options.
Conjugates Experts - 5th Novel Conjugates Summit
Join the Community
Join 80+ scientists driving novel conjugate development, from big pharma discovery teams to emerging biotechs, in a single-track meeting with time to speak with everyone in the room. Download the guide or inquire to secure your place.